News Releases

December 20, 2024

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

December 10, 2024

Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

November 21, 2024

Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split

September 16, 2024

Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024

September 4, 2024

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

August 14, 2024

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

August 13, 2024

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial

August 8, 2024

Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference

July 16, 2024

Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

July 3, 2024

Apollomics Announces Updated Strategic Focus and Leadership Team Changes